Global
English
Global
English
Global
English
Poland
polski
Czechia
Český
Italy
Italiano
Kazakhstan
Қазақ
Slovakia
Slovenský
Spain
Español
Ukraine
Українськa
Uzbekistan
Ўзбекча
Vietnam
Tiếng việt
Adamed across the globe
Global development
A consistently implemented development strategy based on two pillars – innovation and international expansion – has made the pharmaceutical and biotechnology company Adamed a renowned global brand.
The international expansion of our company is based on two business models
in Poland
8 foreign representative offices
and 4 factories - 2 in Poland,
1 in Spain and 1 in Vietnam
available around the world
on a global scale
Spanish expansion – the Riells plant
In July 2026, Adamed Pharma finalized the acquisition of the manufacturing plant of the French company Sanofi in Riells i Viabrea, Spain. As of July 1st, 2026, the factory in Catalonia formally belongs to the Adamed production network. This acquisition strengthens the company's position in Spain and supports its further international expansion.
The Riells plant is Adamed's first production facility in Western Europe. The factory has been operating for 50 years, employs over 200 people, and produces approximately 75 million packs of medicines annually, which are distributed to 77 countries worldwide.
In the coming years, Adamed will carry out a series of investments at the plant to enable the localization of Adamed medicine production there, and will also work on developing team competencies.
Investments in Asia
At the end of 2017, Adamed acquired a majority stake in the local pharmaceutical company Davipharm, and in April 2023 the purchase transaction of the remaining 30 percent of shares was closed - thus Adamed became the sole owner of the Vietnamese company.
This investment is aimed at strengthening Davipharm's market position by introducing EU-GMP standards in the plant and allowing the company to compete with high-quality imported drugs at prices affordable to Vietnamese patients.
Through the purchase transaction 100 percent of shares in Davipharm, Adamed is building a strong platform for further dynamic expansion in the Asia-Pacific area.
Ecupharma acquisition
In 2019, Adamed purchased a block of shares in the Italian company Ecupharma. We formed a strategic partnership with the company to support Adamed’s expansion in the Italian market of cardiac medications, and ultimately also in otherareas of therapy.
Ecupharma is a rapidly growing pharmaceutical company active in the fields of neuropsychiatry and urology. Its product portfolio addresses the needs of people with chronic ailments. The company consistently builds its market standing with the support of its loyal customers. Similarly to Adamed, the company also focuses on health conditions affecting the elderly, seeking to respond to contemporary demographic challenges.